Zhen-Zhen Kong1, Lu Zhang2. 1. Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310000, Zhejiang Province, China. 2. Department of Gastroenterology, The First Affiliated Hospital of Zhejiang Chinese Medical University, Hangzhou 310000, Zhejiang Province, China. zl06302021@163.com.
Core Tip: Cases of esophageal neuroendocrine tumors combined with moderately differentiated gastric cardia adenocarcinoma are very rare. Pathology is the gold standard for diagnosis. Endoscopy and additional surgical resection proved to be successful in our case. Early detection and early treatment are both of great significance to the life and health of patients. Considering the successful resection of this case, we provide this case report to serve as a clinical reference.
INTRODUCTION
At present, cases of esophageal neuroendocrine tumors (NETs) combined with cardia adenocarcinoma are extremely rare worldwide. The presence of cardia cancer and esophageal NETs (E-NETs) in a single patient has not yet been reported. Herein, we describe such a case for clinical reference.
CASE PRESENTATION
Chief complaints
A 76-year-old man was hospitalized due to the presence of a cardia mass.
History of present illness
Previous gastroscopy showed a 0-IIa-like cardia lesions and chronic atrophic gastritis with erosions. The pathological examination revealed the following: Tubular adenoma with high-grade intraepithelial neoplasia; mild chronic atrophic gastritis of the antrum; intestinal metaplasia; and Helicobacter pylori infection (Figure 1).
Figure 1
Full abdominal enhanced computed tomography.
Full abdominal enhanced computed tomography.
History of past illness
The patient’s medical history was unremarkable.
Personal and family history
The patient’s personal/family history was unremarkable.
Physical examination
No remarkable characteristics were found during the physical examination.
Laboratory examinations
The laboratory results were all normal.
Imaging examinations
Previous gastroscopy showed a 0-IIa-like lesion of the cardia and chronic atrophic gastritis with erosions. Enhanced computed tomography scan of the full abdomen was performed after hospitalization, which revealed that the local gastric wall of the gastric cardia was slightly thickened, no significantly enlarged lymph node shadow was seen around the cardia, and the rest of the region appeared unchanged (Figures 2-4).
Figure 2
Endoscopic submucosal dissection. A: Cardia mass; B: Submucosal injection; C: Tick to mark the lesion area; D: Lesion specimen.
Figure 4
Pathology of cardia endoscopic submucosal dissection specimens. A: Moderately differentiated adenocarcinoma of the cardia; B: Esophageal neuroendocrine tumors (G3).
Endoscopic submucosal dissection. A: Cardia mass; B: Submucosal injection; C: Tick to mark the lesion area; D: Lesion specimen.Narrow-band imaging.Pathology of cardia endoscopic submucosal dissection specimens. A: Moderately differentiated adenocarcinoma of the cardia; B: Esophageal neuroendocrine tumors (G3).
FINAL DIAGNOSIS
The final diagnosis was differentiated cardia adenocarcinoma and E-NET (G3).
TREATMENT
Endoscopic submucosal dissection and surgical resection were performed.
OUTCOME AND FOLLOW-UP
The patient was in good general condition without obvious discomfort (Figures 5 and 6).
Representative pathology of excised gastric specimens.
Immunohistochemical staining of esophageal neuroendocrine tumors. A: Syn; B: CD56; C: CgA; D: Ki-67 (25%+).Representative pathology of excised gastric specimens.
DISCUSSION
NENs are a group of highly heterogeneous tumors originating from neuroendocrine cells. They can occur in many parts of the body but are most often found in the digestive system, followed by the lungs. E-NETs are very rare[1], accounting for only 1.4% of all gastrointestinal pancreatic tumors[2] and 0.15%-2.80% of all esophageal tumors[3]. This is due to the poor development of the neuroendocrine system in this area of the body[2]. The incidence rate varies across countries[4]; these tumors are more commonly found in Asian countries than in Western countries[5]. Studies have found that smoking (present in 49%) and drinking (present in 31%) may be a high-risk factor[6,7]. At present, cases of E-NETs combined with cardia adenocarcinoma are extremely rare worldwide, and there are no clinical reports.Pathology is the gold standard for the diagnosis of NETs. The proliferation activity of tumor cells can be evaluated by the number of mitotic figures or the Ki-67 index. According to the 2019 WHO classification standards, NETs are divided into three grades: G1, G2, and G3. The classification criteria are as follows: G1 is defined as < 2 mitotic cells/10 high-power fields (HPFs), G2 as 2-20 cells/10 HPFs, and G3 as > 20 cells/10 HPFs. The Ki-67 index is classified as follows: G1, ≤ 2%; G2, 3%-20%; and G3, > 20%[8]. When the Ki-67 index is inconsistent with the mitotic cell classification, it can instead be classified as high or low. DAXX/ATRX and p53/RB mutations can be used to distinguish G3 NETs from neuroendocrine carcinomas (NECs). According to the guidelines, NETs are < 1 cm in size, are grade G1/G2, have a low metastasis rate (< 3%), and do not infiltrate into the muscularis propria (T1 stage). Thus, they are suitable for endoscopic treatment. For tumors or NECs more than 2 cm in diameter, the metastasis rate can reach as high as 60% to 80%, so radical resection is the first choice.
CONCLUSION
A case of cardia adenocarcinoma combined with E-NETs has not yet been reported. In our patient, after timely endoscopic treatment, pathology revealed that the distance between the cardia cancer and the E-NETs was small, approximately 3 mm, vascular invasion was observed, and the E-NET was determined to be grade G3. According to the treatment guidelines, after the patient received an explanation of their condition, additional surgical procedures were provided in a timely manner. Complete resection of the lesion significantly improved the patient’s quality of life.
Authors: H Sorbye; S Welin; S W Langer; L W Vestermark; N Holt; P Osterlund; S Dueland; E Hofsli; M G Guren; K Ohrling; E Birkemeyer; E Thiis-Evensen; M Biagini; H Gronbaek; L M Soveri; I H Olsen; B Federspiel; J Assmus; E T Janson; U Knigge Journal: Ann Oncol Date: 2012-09-11 Impact factor: 32.976
Authors: Iris D Nagtegaal; Robert D Odze; David Klimstra; Valerie Paradis; Massimo Rugge; Peter Schirmacher; Kay M Washington; Fatima Carneiro; Ian A Cree Journal: Histopathology Date: 2019-11-13 Impact factor: 5.087
Authors: Chang Geun Lee; Yun Jeong Lim; Seun Ja Park; Byung Ik Jang; Seok Reyol Choi; Jae Kwang Kim; Yong-Tae Kim; Joo Young Cho; Chang Hun Yang; Hoon Jai Chun; Si Young Song Journal: BMC Cancer Date: 2014-08-07 Impact factor: 4.430